BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month High - Time to Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s share price reached a new 52-week high on Wednesday . The company traded as high as $9.00 and last traded at $8.99, with a volume of 3116135 shares trading hands. The stock had previously closed at $8.63.

Analyst Ratings Changes

BCRX has been the topic of a number of analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. JMP Securities restated a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Evercore ISI boosted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. Needham & Company LLC boosted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday, January 13th. Finally, Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.50.

BioCryst Pharmaceuticals Price Performance

The company has a market capitalization of $1.87 billion, a PE ratio of -14.84 and a beta of 1.75. The stock has a 50-day simple moving average of $7.86 and a 200 day simple moving average of $7.77.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $46,000. R Squared Ltd acquired a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth $48,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 1,322 shares during the last quarter. KBC Group NV raised its holdings in shares of BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 4,537 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at $80,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.